Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24777122 | 0.86 | HTR2C (0.35) | KDM4ETP53HTR2CSLC6A4EPHX2 | |
| SCHEMBL16373730 | 0.86 | RAB9A (0.36) | KDM4ETP53HTR2CSLC6A4EPHX2 | |
| SCHEMBL24777116 | 0.80 | METTL3 (0.34) | KDM4ETP53HTR2CSLC6A4HTR2A | |
| SCHEMBL178474 | 0.77 | — | — | |
| SCHEMBL24777115 | 0.73 | DYRK1A (0.39) | KDM4ETP53HTR2CSLC6A4EPHX2 | |
| SCHEMBL18869734 | 0.73 | GBA1 (0.37) | KDM4ETP53 | |
| SCHEMBL24777118 | 0.72 | CASR (0.33) | KDM4ETP53HTR2CSLC6A4EPHX2 | |
| SCHEMBL21322298 | 0.68 | EPHX2 (0.38) | EPHX2KMT2AMAPT | |
| SCHEMBL23948656 | 0.66 | EPHX2 (0.43) | EPHX2KMT2AMAPT | |
| SCHEMBL13853632 | 0.65 | EPHX2 (0.41) | EPHX2KMT2AMAPTCACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | KDM4E 3632/4885TP53 4583/4885HTR2C 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.